DaVita Exceeds Q4 Earnings and Issues 2026 EPS Guidance Above Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Source: stocktwits
- Earnings Beat: DaVita reported Q4 adjusted EPS of $3.40, surpassing the consensus estimate of $3.19, with revenue of $3.62 billion also exceeding expectations of $3.51 billion, indicating strong financial performance and market confidence.
- Optimistic 2026 Outlook: The company forecasts adjusted EPS for 2026 between $13.6 and $15, above the consensus of $12.74, alongside projected adjusted operating income growth to $2.085 billion to $2.235 billion and free cash flow of $1 billion to $1.25 billion, highlighting significant future growth potential.
- IKC Profitability Ahead of Schedule: DaVita's Integrated Kidney Care (IKC) unit achieved profitability in 2025, a year ahead of its original target, with Q4 IKC adjusted operating income at $46 million, validating the effectiveness of its clinical care model.
- Cost Reduction for Patients: IKC patients were found to be three times less costly in the first 180 days of treatment and more likely to start dialysis with permanent vascular access, demonstrating the company's success in improving patient outcomes and reducing healthcare costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to fall
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 198.520
Low
144.00
Averages
162.50
High
190.00
Current: 198.520
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Four High-Growth GARP Stocks for 2026
- DaVita's Growth Potential: DaVita, a leading provider of dialysis services in the U.S., demonstrated strong momentum in Q1 2026 with an impressive long-term growth rate of 20.2%, making it an ideal GARP investment choice due to its reasonable PEG and P/E ratios, showcasing sustainable profitability.
- Integra's Market Demand: Integra LifeSciences leads in regenerative medicine, with a projected five-year growth rate of 5.9% for 2026, as steady demand in neurosurgery and ENT products highlights the company's strong competitive position in the medical device market.
- Braskem's Industry Position: Braskem manufactures petrochemical products in Brazil and internationally, with an expected long-term growth rate of 16.8%, and its superior value and growth scores make it stand out in GARP investment strategies, reflecting robust performance in the global market.
- LyondellBasell's Historical Growth: LyondellBasell holds a significant position in the global plastics and chemicals industry, boasting a historical growth rate of 49.4%, and its reasonable PEG and P/E ratios position it as a preferred choice for GARP investors, demonstrating strong market potential.
See More
DaVita Unveils 2030 Community Care Commitments
- Advancing Industry-Leading Care: In 2025, DaVita educated over 40,000 individuals through its Kidney Smart® classes, reaching a total of more than 300,000, while supporting over 8,000 patients in receiving kidney transplants, with a goal to further enhance patient care quality by 2030.
- Driving Economic Mobility and Teammate Engagement: DaVita achieved an 85% teammate engagement score in 2025, logged over 218,000 hours of community service, and supported more than 400 teammates in pursuing advanced nursing degrees, aiming to continue fostering employee development and community involvement by 2030.
- Strengthening Communities and Environmental Resilience: DaVita has achieved 100% renewable energy use across its operations and conserved 468 million gallons of water, with plans to further enhance environmental sustainability in the future.
- External Recognition and Impact: DaVita's efforts in sustainability, workplace culture, and corporate governance have garnered external recognition, showcasing its ongoing commitment to elevating kidney care standards and community impact.
See More
DaVita Unveils 2030 Community Care Commitments
- Patient Care Enhancement: DaVita aims to improve patient quality of life by reducing avoidable hospitalizations and empowering 150,000 patients to make informed treatment choices through kidney education by 2030, significantly enhancing patient satisfaction and health outcomes.
- Driving Economic Mobility: Achieving an 85% teammate engagement score in 2025, DaVita plans to maintain an engagement rate of over 80% annually while supporting 2,000 new nurses through development programs, thereby strengthening team cohesion and career advancement opportunities.
- Strengthening Community Resilience: With 100% renewable energy already in use, DaVita plans to support philanthropic investments benefiting 400,000 people, further enhancing its impact on sustainability and ensuring continuity of patient care.
- External Recognition: DaVita has received multiple external honors for its sustainability, workplace culture, and corporate governance, including recognition from Time magazine as one of the World's Most Sustainable Companies and accolades from Fortune as an employer of choice, solidifying its leadership position in the industry.
See More
Greg Abel's First Shareholder Meeting as CEO Receives Mixed Reviews
- Attendance at Shareholder Meeting: Greg Abel's first annual meeting as CEO saw attendance at just over half capacity, indicating a significant drop in draw compared to the Buffett and Munger era, although it still surpassed typical corporate annual meetings.
- Capital Allocation Concerns: Abel's failure to provide clear guidance on the future of Berkshire's equity portfolio and substantial cash reserves has heightened investor concerns regarding the company's capital allocation strategy, potentially impacting market confidence in Berkshire.
- Lackluster Buyback Performance: Despite announcing a resumption of stock buybacks, Berkshire repurchased only $234 million in shares during Q1, falling short of market expectations and possibly undermining investor trust in the company's buyback strategy.
- New CFO Compensation: The new CFO, Charles Chang, will receive an annual salary of $8 million, a significant increase compared to the previous CFO Marc Hamburg's total compensation of $4.3 million, raising potential shareholder concerns about the reasonableness of executive pay.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
DaVita to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will engage in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM EDT, highlighting the company's commitment to investor relations.
- Global Patient Reach: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S. and 596 in 14 other countries, showcasing its extensive global footprint in kidney care.
- Leadership in Clinical Quality: With over 25 years of experience, DaVita has led the kidney care sector by reducing hospitalizations, improving mortality rates, and enhancing health access, thereby pushing the kidney care community to adopt higher quality standards for patient care.
- Comprehensive Care Model: DaVita is committed to supporting patients at every stage of their kidney health journey, providing care in homes, dialysis centers, hospitals, and skilled nursing facilities, ensuring high-quality care across various settings.
See More
Four High-Growth GARP Stocks for 2026
- DaVita's Growth Potential: DaVita, a leading provider of dialysis services in the U.S., demonstrated strong momentum in Q1 2026 with an impressive long-term growth rate of 20.2%, making it an ideal GARP investment choice due to its reasonable PEG and P/E ratios, showcasing sustainable profitability.
- Integra's Market Demand: Integra LifeSciences leads in regenerative medicine, with a projected five-year growth rate of 5.9% for 2026, as steady demand in neurosurgery and ENT products highlights the company's strong competitive position in the medical device market.
- Braskem's Industry Position: Braskem manufactures petrochemical products in Brazil and internationally, with an expected long-term growth rate of 16.8%, and its superior value and growth scores make it stand out in GARP investment strategies, reflecting robust performance in the global market.
- LyondellBasell's Historical Growth: LyondellBasell holds a significant position in the global plastics and chemicals industry, boasting a historical growth rate of 49.4%, and its reasonable PEG and P/E ratios position it as a preferred choice for GARP investors, demonstrating strong market potential.
See More
DaVita Unveils 2030 Community Care Commitments
- Advancing Industry-Leading Care: In 2025, DaVita educated over 40,000 individuals through its Kidney Smart® classes, reaching a total of more than 300,000, while supporting over 8,000 patients in receiving kidney transplants, with a goal to further enhance patient care quality by 2030.
- Driving Economic Mobility and Teammate Engagement: DaVita achieved an 85% teammate engagement score in 2025, logged over 218,000 hours of community service, and supported more than 400 teammates in pursuing advanced nursing degrees, aiming to continue fostering employee development and community involvement by 2030.
- Strengthening Communities and Environmental Resilience: DaVita has achieved 100% renewable energy use across its operations and conserved 468 million gallons of water, with plans to further enhance environmental sustainability in the future.
- External Recognition and Impact: DaVita's efforts in sustainability, workplace culture, and corporate governance have garnered external recognition, showcasing its ongoing commitment to elevating kidney care standards and community impact.
See More
DaVita Unveils 2030 Community Care Commitments
- Patient Care Enhancement: DaVita aims to improve patient quality of life by reducing avoidable hospitalizations and empowering 150,000 patients to make informed treatment choices through kidney education by 2030, significantly enhancing patient satisfaction and health outcomes.
- Driving Economic Mobility: Achieving an 85% teammate engagement score in 2025, DaVita plans to maintain an engagement rate of over 80% annually while supporting 2,000 new nurses through development programs, thereby strengthening team cohesion and career advancement opportunities.
- Strengthening Community Resilience: With 100% renewable energy already in use, DaVita plans to support philanthropic investments benefiting 400,000 people, further enhancing its impact on sustainability and ensuring continuity of patient care.
- External Recognition: DaVita has received multiple external honors for its sustainability, workplace culture, and corporate governance, including recognition from Time magazine as one of the World's Most Sustainable Companies and accolades from Fortune as an employer of choice, solidifying its leadership position in the industry.
See More
Greg Abel's First Shareholder Meeting as CEO Receives Mixed Reviews
- Attendance at Shareholder Meeting: Greg Abel's first annual meeting as CEO saw attendance at just over half capacity, indicating a significant drop in draw compared to the Buffett and Munger era, although it still surpassed typical corporate annual meetings.
- Capital Allocation Concerns: Abel's failure to provide clear guidance on the future of Berkshire's equity portfolio and substantial cash reserves has heightened investor concerns regarding the company's capital allocation strategy, potentially impacting market confidence in Berkshire.
- Lackluster Buyback Performance: Despite announcing a resumption of stock buybacks, Berkshire repurchased only $234 million in shares during Q1, falling short of market expectations and possibly undermining investor trust in the company's buyback strategy.
- New CFO Compensation: The new CFO, Charles Chang, will receive an annual salary of $8 million, a significant increase compared to the previous CFO Marc Hamburg's total compensation of $4.3 million, raising potential shareholder concerns about the reasonableness of executive pay.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
DaVita to Participate in BofA Health Conference
- Executive Participation: DaVita's CFO Joel Ackerman and VP of Investor Relations Nic Eliason will engage in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 5:20 PM EDT, highlighting the company's commitment to investor relations.
- Global Patient Reach: As of March 31, 2026, DaVita serves approximately 296,300 patients across 3,262 outpatient dialysis centers, with 2,666 located in the U.S. and 596 in 14 other countries, showcasing its extensive global footprint in kidney care.
- Leadership in Clinical Quality: With over 25 years of experience, DaVita has led the kidney care sector by reducing hospitalizations, improving mortality rates, and enhancing health access, thereby pushing the kidney care community to adopt higher quality standards for patient care.
- Comprehensive Care Model: DaVita is committed to supporting patients at every stage of their kidney health journey, providing care in homes, dialysis centers, hospitals, and skilled nursing facilities, ensuring high-quality care across various settings.
See More
